...
机译:哮喘的流感负担,预防和治疗 - 哮喘工作队中EAACI eAaci流感的审查
Centre for Inflammation ResearchUniversity of EdinburghEdinburgh UK;
Respiratory SciencesImperial College LondonLondon UK;
Respiratory SciencesImperial College LondonLondon UK;
Department of Medical Sciences and Public Health “M. Aresu”University of CagliariCagliari Italy;
Department of Medical Sciences and Public Health “M. Aresu”University of CagliariCagliari Italy;
Department of Pediatric AllergologyKing's CollegeLondon UK;
Faculty of MedicineUniversity of SouthamptonNewport Isle of Wight UK;
Faculty of MedicineUniversity of SouthamptonNewport Isle of Wight UK;
Swiss Institute of Allergy and Asthma ResearchUniversity of ZurichDavos Switzerland;
Department of Allergy and Clinical ImmunologyTransylvania University BrasovBrasov Romania;
Department of PaediatricsImperial College LondonLondon UK;
Personalized MedicineHumanitas UniversityMilan Italy;
Department of Medical MicrobiologyNational Kapodistrian University of AthensAthens Greece;
National Research Center Institute of Immunology of Federal Medicobiological AgencyMoscow Russia;
National Research Center Institute of Immunology of Federal Medicobiological AgencyMoscow Russia;
Division of Infection Inflammation &
Respiratory MedicineThe University of ManchesterManchester UK;
Department of Health and Hospital ManagementKorangi CreekKarachi 75190 Pakistan;
Division of Population MedicineCardiff UniversityWales UK;
Institute of Laboratory Medicine and PathobiochemistryPhilipps University MarburgMarburg Germany;
Asthma UK Centre for Applied ResearchThe University of EdinburghEdinburgh UK;
Institute of Laboratory Medicine and PathobiochemistryPhilipps University MarburgMarburg Germany;
antivirals; heath care utilization; respiratory; vaccination; viral infection;
机译:哮喘的流感负担,预防和治疗 - 哮喘工作队中EAACI eAaci流感的审查
机译:生物学(Benralizumab,Dupilumab,Mepolizumab,Omalizumab和Reslizumab)治疗的疗效和安全性对严重的嗜酸性哮喘。 对EAACI指南的系统审查 - 关于在严重哮喘中使用生物学的建议
机译:对生物(Benralizumab,Dupilumab和Omalizumab)治疗的疗效和安全性严重过敏性哮喘:对EAACI指南的系统审查 - 关于使用生物学在严重哮喘中使用的建议
机译:个性化治疗方案的哮喘严重程度和哮喘发作的个性化预测
机译:2002年至2012年在纽约市进行的流感和哮喘住院治疗。
机译:涉及美国过敏哮喘和免疫学学会(AAAAI)的联合工作组的工作组报告;食品过敏过敏反应皮肤病学和药物过敏(FADDA)(食品委员会的不良反应和药物生物制品和乳胶委员会的不良反应);和疾病预防控制中心肉毒杆菌中毒临床治疗指南工作组-对肉毒杆菌毒素的过敏反应:系统评价
机译:哮喘的流感负担,预防和治疗 - EaaCI流感在哮喘特遣部队的范围审查
机译:国家哮喘教育和预防计划工作组成本效益,护理质量和哮喘护理融资。